Sabouret Pierre, Bricard Marie, Hermann Marie-Annick, Cotté Francois-Emery, Deret-Bixio Leyla, Rushton-Smith Sophie
Heart Institute, Department of Cardiology, Pitié-Salpétrière Hospital, Pierre-and-Marie-Curie University, 75013 Paris, France.
Bristol-Myers Squibb, 92500 Rueil-Malmaison, France.
Arch Cardiovasc Dis. 2015 Nov;108(11):544-53. doi: 10.1016/j.acvd.2015.05.005. Epub 2015 Jun 22.
General practitioners (GPs) play a pivotal role in the long-term management of patients with atrial fibrillation (AF), including anticoagulant prophylaxis for stroke prevention.
To investigate the antithrombotic prescription behaviours of GPs in France and compare them with the European Society of Cardiology (ESC) guidelines for stroke prevention, and to identify the major determinants of use of antithrombotic therapy.
We conducted a cross-sectional survey, using data from the French Longitudinal Patient Database, on the use of antithrombotic treatments for stroke prevention in 15,623 patients (≥18years of age) with AF who attended at least one GP consultation between July 2010 and June 2011. Data were collected on patient baseline characteristics, stroke risk factors, and prescription of antithrombotic drugs.
The mean age was 74.6±11.1years, 59.5% were men, and 83.1% had a CHADS2 score≥1. Over half (52.6%) of the patients with a CHADS2 score≥1 received a vitamin K antagonist (alone or in combination with an antiplatelet), 19.3% received aspirin alone, and 23.4% received no antithrombotic therapy; 3.6% of the patients received dual antiplatelet therapy and 1.1% clopidogrel alone. Over half of the patients (56.3%) were treated in accordance with the ESC 2010 guidelines. Of the remaining patients, 19.4% received no treatment, 13.0% were inadequately treated, and 11.2% were over-treated. Factors associated with antithrombotic treatment were anti-arrhythmic therapy, higher stroke risk, presence of atherothrombotic disease, and use of non-steroidal anti-inflammatory drugs. Female gender was associated with a lower likelihood of antithrombotic treatment.
In this large French study, approximately 45% of thromboembolic high-risk patients were either not treated or inadequately treated. Better compliance with evidence-based guidelines is needed to reduce the burden of stroke in the AF population.
全科医生(GPs)在心房颤动(AF)患者的长期管理中发挥着关键作用,包括预防中风的抗凝治疗。
调查法国全科医生的抗血栓处方行为,并将其与欧洲心脏病学会(ESC)的中风预防指南进行比较,以确定使用抗血栓治疗的主要决定因素。
我们进行了一项横断面调查,使用法国纵向患者数据库的数据,调查了2010年7月至2011年6月期间至少就诊过一次全科医生的15623名年龄≥18岁的房颤患者预防中风的抗血栓治疗使用情况。收集了患者的基线特征、中风危险因素和抗血栓药物处方的数据。
平均年龄为74.6±11.1岁,59.5%为男性,83.1%的CHADS2评分≥1。CHADS2评分≥1的患者中,超过一半(52.6%)接受了维生素K拮抗剂(单独或与抗血小板药物联合使用),19.3%仅接受阿司匹林治疗,23.4%未接受抗血栓治疗;3.6%的患者接受了双联抗血小板治疗。,1.1%仅接受氯吡格雷治疗。超过一半的患者(56.3%)按照ESC 2010指南进行治疗。其余患者中,19.4%未接受治疗,13.0%治疗不充分,11.2%治疗过度。与抗血栓治疗相关的因素包括抗心律失常治疗、中风风险较高、存在动脉粥样硬化血栓形成疾病以及使用非甾体抗炎药。女性接受抗血栓治疗的可能性较低。
在这项大型法国研究中,约45%的血栓栓塞高危患者未得到治疗或治疗不充分。需要更好地遵循循证指南,以减轻房颤人群的中风负担。